Novel and Existing Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Predictors of Optimal Resectability in Malignant Peritoneal Mesothelioma-Reference-Cited by-同舟云学术

Novel and Existing Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Predictors of Optimal Resectability in Malignant Peritoneal Mesothelioma

Published:2009-01 Issue:1 Volume:16 Page:152-158
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Foster Jason M.,Gatalica Zoran,Lilleberg Stan,Haynatzki Gleb,Loggie Brian W.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-008-0206-6.pdf

Reference52 articles.

1. Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.

2. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.

3. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol. 2002;29:51–61.

4. Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005;104:2181–8.

5. Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolving Management of Peritoneal Surface Malignancies;Current Problems in Surgery;2021-04

2. EGFR-targeting antitumor therapy: Neuregulins or antibodies?;European Journal of Pharmaceutical Sciences;2021-03

3. Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma;Expert Opinion on Drug Delivery;2019-04-03

4. History Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis and Evolution and Contemporary Application in Peritoneal Mesothelioma;Caring for Patients with Mesothelioma: Principles and Guidelines;2019

5. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives;Annals of Gastroenterology;2018